Contact the Editorial Desk

Editorial correspondence

Southern Peptide Co welcomes correspondence on the research record: a citation quoted inaccurately, a newly published trial, a regulatory update that changes an approval or WADA-prohibited status, or a peer-reviewed study on GHK-Cu, TB-500, or BPC-157 that should be added to the references page. This class of correction is the most useful message this desk receives.

The most actionable submissions specify the page in question, the exact passage being corrected, and a supporting reference — a DOI or PubMed identifier where possible — so a proposed change can be verified against its source before it is acted on.

Editorial mailbox: editors@southernpeptideco.com

What this desk cannot do

Southern Peptide Co is a literature briefing, not a clinical service or product vendor, so it cannot advise on or recommend human use of any peptide discussed here, suggest a dose or route of administration for any individual, evaluate whether a cited finding applies to a specific person's situation, or sell, source, or help locate any compound from any supplier. It also cannot advise athletes subject to anti-doping testing, given that two of the three compounds discussed here fall under WADA-prohibited categories.

None of the compounds covered on this site is an approved systemic medicine. Readers seeking medical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.